Zhejiang Shengda Pharm (603079) — Working Capital to Net Assets Ratio
Zhejiang Shengda Pharm (603079) has a Working Capital to Net Assets ratio of 47.6% as of March 2026. Working capital of CN¥775.94 Million (current assets of CN¥986.41 Million minus current liabilities of CN¥210.47 Million) is measured against net assets of CN¥1.63 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See financial agility of Zhejiang Shengda Pharm to measure the company's free cash flow as a share of total liabilities.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Zhejiang Shengda Pharm Working Capital to Net Assets (2012–2025)
This chart shows how Zhejiang Shengda Pharm's Working Capital to Net Assets ratio has evolved across 14 annual periods from 2012 to 2025. As of March 2026, the ratio stands at 47.6%, reflecting working capital of CN¥775.94 Million against net assets of CN¥1.63 Billion CNY. See Zhejiang Shengda Pharm (603079) liquidity interval to measure how many days the company can operate on defensive assets alone.
Annual Working Capital to Net Assets for Zhejiang Shengda Pharm (2012–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Zhejiang Shengda Pharm from 2012 to 2025, covering 14 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see Zhejiang Shengda Pharm (603079) market capitalisation.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 47.3% | CN¥763.71 Million | CN¥1.61 Billion | CN¥1.01 Billion | CN¥246.70 Million | ▲ +11.7 pp |
| 2024 | 35.6% | CN¥457.38 Million | CN¥1.28 Billion | CN¥708.77 Million | CN¥251.38 Million | ▲ +4.2 pp |
| 2023 | 31.5% | CN¥399.69 Million | CN¥1.27 Billion | CN¥695.15 Million | CN¥295.45 Million | ▼ -4.6 pp |
| 2022 | 36.1% | CN¥484.90 Million | CN¥1.34 Billion | CN¥780.36 Million | CN¥295.46 Million | ▼ -1.8 pp |
| 2021 | 37.9% | CN¥506.32 Million | CN¥1.34 Billion | CN¥918.81 Million | CN¥412.50 Million | ▼ -1.6 pp |
| 2020 | 39.4% | CN¥522.39 Million | CN¥1.33 Billion | CN¥881.15 Million | CN¥358.76 Million | ▲ +1.2 pp |
| 2019 | 38.3% | CN¥348.93 Million | CN¥911.71 Million | CN¥720.45 Million | CN¥371.53 Million | ▲ +19.8 pp |
| 2018 | 18.5% | CN¥152.93 Million | CN¥828.42 Million | CN¥569.78 Million | CN¥416.84 Million | ▼ -33.7 pp |
| 2017 | 52.1% | CN¥400.87 Million | CN¥768.71 Million | CN¥616.33 Million | CN¥215.47 Million | ▲ +26.0 pp |
| 2016 | 26.1% | CN¥115.00 Million | CN¥440.02 Million | CN¥386.39 Million | CN¥271.39 Million | ▲ +0.0 pp |
| 2015 | 26.1% | CN¥114.68 Million | CN¥439.09 Million | CN¥297.41 Million | CN¥182.73 Million | ▲ +21.3 pp |
| 2014 | 4.8% | CN¥15.57 Million | CN¥324.87 Million | CN¥220.64 Million | CN¥205.06 Million | ▼ -12.9 pp |
| 2013 | 17.7% | CN¥49.72 Million | CN¥281.09 Million | CN¥232.35 Million | CN¥182.63 Million | ▲ +36.3 pp |
| 2012 | -18.6% | CN¥-34.65 Million | CN¥185.99 Million | CN¥220.71 Million | CN¥255.36 Million | — |